Manufacturer
Servier
Contents
Perindopril arginine 10 mg, indapamide 2.5 mg, amlodipine 5 mg.
Indication
Substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed-dose combination & amlodipine, taken at the same dose level.
Instruction
1 tab as a single dose daily, preferably taken in the morning. Should be taken on an empty stomach: Take before meal.
Drug interaction
Increased risk of hyperkalaemia w/ aliskiren, K salts, K-sparing diuretics, ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents eg, ciclosporin or tacrolimus, trimethoprim, dantrolene (infusion). Reversible increases in serum lithium conc. Increased risk of adverse events w/ estramustine. Increased bioavailability by grapefruit or grapefruit juice. Increased antihypertensive effect w/ baclofen, NSAIDs, imipramine-like antidepressants (tricyclics), neuroleptics. Increased risk of hypoglycemia w/ antidiabetic agents. Increased risk of hypotension w/ non-K-sparing diuretics, nitroglycerin, other nitrates, other vasodilators, thiazide or loop diuretics. Risk of hypokalaemia w/ Torsade de pointes inducing agents eg, class IA antiarrhythmic agents (eg, quinidine, hydroquinidine, disopyramide), class III antiarrhythmic agents (eg, amiodarone, dofetilide, ibutilide, bretylium, sotalol), neuroleptics (eg, chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine, pimozide), benzamides (eg, amisulpride, sulpiride, sultopride, tiapride), butyrophenones (eg, droperidol, haloperidol), bepridil, cisapride, diphemanil, IV erythromycin & vincamine, halofantrine, mizolastine, moxifloxacin, pentamidine, sparfloxacin, methadone, astemizole, terfenadine, IV amphotericin B, systemic glucocorticoids & mineralocorticoids, tetracosactide, stimulant laxatives, cardiac glycosides. Caution w/ CYP3A4 inducers & inhibitors. Increased risk of leucopenia w/ allopurinol, cytostatic or immunosuppressive agents, systemic corticosteroids or procainamide. Enhanced hypotensive effects of certain anaesth. Increased risk of angioedema w/ gliptines (eg, linagliptine, saxagliptine, sitagliptine, vidagliptine). Reduced antihypertensive effects by sympathomimetics. Increased nitritoid reactions w/ injectable gold (Na aurothiomalate). Lactic acidosis due to metformin. Increased risk of acute renal insufficiency w/ iodinated contrast media, ciclosporin. Increase simvastatin exposure.
Malaysia
